Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000779 · ClinicalTrials.gov registry record · Phase 1

A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3

A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 1
Development phase
130
Enrollment target
10
Study locations

NCT00000779 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 130 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (71% lower). The trial reports 10 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000779, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 1
Development phase
130 participants
Enrollment target
10
Study locations

Study Summary

PRIMARY: To compare the immunogenicity and safety of each of several HIV-1 derived immunogens versus control in HIV-infected individuals with CD4 counts greater than or equal to 500 cells/mm3. SECONDARY: To determine whether significant advantages to any one vaccine exist. Before large clinical trials of anti-HIV vaccines are undertaken, it is important to determine whether there are significant advantages to any one of the vaccines currently offered for such studies.

Conditions Studied

HIV Infections

Interventions

  • BIOLOGICAL rgp120/HIV-1MN
  • BIOLOGICAL MF59
  • BIOLOGICAL Aluminum hydroxide
  • BIOLOGICAL rgp120/HIV-1 SF-2
  • BIOLOGICAL rgp120/HIV-1IIIB

Study Locations (10)

California

  • UCLA CARE Center CRS - Los Angeles
  • Stanford CRS - Palo Alto
  • Santa Clara Valley Med. Ctr. - San Jose
  • San Mateo County AIDS Program - San Mateo

Massachusetts

  • Massachusetts General Hospital ACTG CRS - Boston
  • Bmc Actg Crs - Boston
  • Beth Israel Deaconess Med. Ctr., ACTG CRS - Boston

Colorado

  • University of Colorado Hospital CRS - Aurora

New York

  • NY Univ. HIV/AIDS CRS - New York

Washington

  • University of Washington AIDS CRS - Seattle

Trial Details

FieldValue
Enrollment Target 130 participants
Est. Completion 1996-09
Phase Phase 1

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00000779

The ClinicalTrials.gov registry entry for NCT00000779 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (71% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 5 interventions - of which rgp120/HIV-1MN is the first listed.

NCT00000779 reports 10 study locations spanning 5 distinct geographic areas - top geographies include California, Massachusetts, Colorado.

Frequently Asked Questions

What is clinical trial NCT00000779 about?

NCT00000779 is a clinical study titled "A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3". PRIMARY: To compare the immunogenicity and safety of each of several HIV-1 derived immunogens versus control in HIV-infected individuals with CD4 counts greater than or equal to 500 cells/mm3. SECONDARY: To determine whether significant advantages to any one vaccine exist. Before large clinical tr...

What is the current status of trial NCT00000779?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 130 participants. Estimated completion is 1996-09.

What conditions does trial NCT00000779 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00000779?

The interventions under investigation include: rgp120/HIV-1MN (BIOLOGICAL), MF59 (BIOLOGICAL), Aluminum hydroxide (BIOLOGICAL), rgp120/HIV-1 SF-2 (BIOLOGICAL), rgp120/HIV-1IIIB (BIOLOGICAL).

Who is sponsoring clinical trial NCT00000779?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000779 being conducted?

This trial has 10 study locations across California, Colorado, Massachusetts, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.